IMUNON (IMNN) reported second-quarter 2026 financial results and business updates, including progress in Phase 3 development of IMNN-001 for newly diagnosed advanced ovarian cancer. The company reported a net loss of $2.8 million, or $0.54 per share, for the quarter ended June 30, 2026.
The company said enrollment in the Phase 3 OVATION 3 study is expected to be completed by the first half of 2029, supported by Phase 2 data showing a 14.7-month median overall survival increase for IMNN-001 plus standard of care chemotherapy compared with standard of care alone.
- Second-quarter operating expenses were $2.8 million, unchanged from the second quarter of 2025.
- Research and development expenses were $1.5 million in the quarter, up from $1.2 million a year earlier.
- General and administrative expenses were $1.3 million, down from $1.5 million in the prior-year period.
- Cash and cash equivalents were $6.9 million as of June 30, 2026.
- IMUNON entered financing agreements on June 4 with aggregate gross proceeds of $10 million.
- The company plans an R&D Day on September 23, 2026, in New York.
$IMNN Insider Trading Activity
$IMNN insiders have traded $IMNN stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $IMNN stock by insiders over the last 6 months:
- SUSAN EYLWARD (General Counsel and Corp Sec) has made 0 purchases and 3 sales selling 14,870 shares for an estimated $26,233.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$IMNN Hedge Fund Activity
We have seen 7 institutional investors add shares of $IMNN stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 81,444 shares (+30.5%) to their portfolio in Q1 2026, for an estimated $239,445
- DRW SECURITIES, LLC removed 58,830 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $172,960
- HRT FINANCIAL LP added 12,055 shares (+inf%) to their portfolio in Q1 2026, for an estimated $35,441
- GEODE CAPITAL MANAGEMENT, LLC added 11,989 shares (+56.5%) to their portfolio in Q1 2026, for an estimated $35,247
- TOWER RESEARCH CAPITAL LLC (TRC) added 1,815 shares (+3558.8%) to their portfolio in Q1 2026, for an estimated $5,336
- UBS GROUP AG removed 1,022 shares (-64.0%) from their portfolio in Q1 2026, for an estimated $3,004
- MORGAN STANLEY added 71 shares (+2.4%) to their portfolio in Q1 2026, for an estimated $208
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
